Last reviewed 2026-04-22 · How we verify

Levofloxacin-Amox/clav.

Levofloxacin-Amox/clav. is a Fluoroquinolone + Beta-lactam/Beta-lactamase inhibitor combination Small molecule drug developed by Buddhist Tzu Chi General Hospital. It is currently FDA-approved for Bacterial infections (respiratory tract, urinary tract, skin and soft tissue infections). Also known as: Levofloxacin(Cravit), Amoxicillin/clavulanate(Augmentin) and, Rabeprazole(Pariet) for 7 days..

This is a fixed-dose combination of levofloxacin (a fluoroquinolone antibiotic) and amoxicillin/clavulanic acid (a beta-lactam with beta-lactamase inhibitor) that together provide broad-spectrum bacterial coverage through inhibition of DNA gyrase and bacterial cell wall synthesis.

This is a fixed-dose combination of levofloxacin (a fluoroquinolone antibiotic) and amoxicillin/clavulanic acid (a beta-lactam with beta-lactamase inhibitor) that works synergistically to inhibit bacterial cell wall synthesis and DNA replication. Used for Bacterial infections susceptible to both levofloxacin and amoxicillin/clavulanic acid (respiratory, urinary tract, skin and soft tissue infections).

At a glance

Mechanism of action

Levofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in gram-positive and gram-negative bacteria. Amoxicillin/clavulanic acid works synergistically by inhibiting bacterial cell wall peptidoglycan cross-linking, while clavulanic acid protects amoxicillin from beta-lactamase degradation. The combination provides enhanced coverage against resistant organisms.

Approved indications

• Bacterial infections (respiratory tract, urinary tract, skin and soft tissue infections)

Common side effects

• Nausea
• Diarrhea
• Headache
• Tendinopathy
• QT prolongation

Key clinical trials

• Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP (PHASE4)
• A Platform Trial for Gram Negative Bloodstream Infections (NA)
• Early Antibiotics After Aspiration in ICU Patients (PHASE4)
• Comparing Oral Versus Parenteral Antimicrobial Therapy (PHASE4)
• Effect of Topical Sinonasal Antibiotics (PHASE2)
• An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB) (PHASE2)
• BALANCE+ Vanguard Phase (NA)
• Efficacy of Oral vs IV Antibiotics in the Treatment of Orofacial Osteomyelitis (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Levofloxacin-Amox/clav. CI brief — competitive landscape report
• Levofloxacin-Amox/clav. updates RSS · CI watch RSS
• Buddhist Tzu Chi General Hospital portfolio CI

Frequently asked questions about Levofloxacin-Amox/clav.

Related

• Drug class: All Fluoroquinolone + Beta-lactam/Beta-lactamase inhibitor combination drugs
• Target: All drugs targeting Bacterial DNA gyrase, topoisomerase IV, penicillin-binding proteins
• Manufacturer: Buddhist Tzu Chi General Hospital — full pipeline
• Therapeutic area: All drugs in Infectious Disease
• Indication: Drugs for Bacterial infections (respiratory tract, urinary tract, skin and soft tissue infections)
• Also known as: Levofloxacin(Cravit), Amoxicillin/clavulanate(Augmentin) and, Rabeprazole(Pariet) for 7 days.
• Compare: Levofloxacin-Amox/clav. vs similar drugs
• Pricing: Levofloxacin-Amox/clav. cost, discount & access